ARQ 197 in Subjects With Metastatic Solid Tumors

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Status and phase

Completed

Phase 1

Conditions

Tumor

Cancer

Treatments

Drug: ARQ 197

Study type

Interventional

Funder types

Industry

Identifiers

NCT00302172

ARQ 197-101

Details and patient eligibility

About

To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.

Full description

To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197 given orally. This is an open label, dose escalation study of ARQ 197 administered orally at a starting dose of 10 mg bid (20 mg/day).

Enrollment

78 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Signed written informed consent must be obtained and documented according to ICH GCP, the local regulatory requirements, and permission to use private health information in accordance with HIPPA prior to study-specific screening procedures
A histologically or cytologically confirmed RCC or other c-Met expression tumors that is metastatic
Patient must have available archival tumor tissue or accessible tumor that is safely amenable to tumor biopsy
≥ 18 years of age
Measurable disease as defined by Response Evaluation Criteria in Solid Tumors
Karnofsky performance status ≥ 70%
Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last ARQ 197 dose
Females of childbearing potential must have a negative serum pregnancy test
Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 × upper limit of normal (ULN) or ≤ 5.0 × ULN with metastatic liver disease.
Hemoglobin (Hgb) ≥ 10 g/dl
Total bilirubin ≤ 1.5 × ULN
Creatinine ≤ 1.5 x ULN
Absolute neutrophil count ≥ 1.5 x 10^9/L
Platelets ≥ 100 x 10^9/L

Exclusion criteria

Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of first dose
Surgery within 4 weeks prior to first dose
Known brain metastases
Pregnant or breastfeeding
Significant gastrointestinal disorder(s), in the opinion of the Principal Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection)
Unable or unwilling to swallow ARQ 197 capsules twice daily
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
Bradycardia at baseline or known history of arrhythmia